Extending survival in gliomas: surgical resection or immunotherapy?
Hall
Walter A
WA
Departments of Neurosurgery, Radiation Oncology and Radiology, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA.
D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000008:administration & dosage; D003713:Dendritic Cells / Q000276:immunology; D004185:Disability Evaluation; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007430:Intraoperative Care; D017567:Karnofsky Performance Status; D008279:Magnetic Resonance Imaging; D019635:Neurosurgical Procedures; D015514:Oncogene Proteins, Fusion / Q000008:administration & dosage; D018579:Patient Selection; D011993:Recombinant Fusion Proteins
D019496:Cancer Vaccines; D015514:Oncogene Proteins, Fusion; D011993:Recombinant Fusion Proteins; C471586:diphtheria toxin-urokinase fusion protein, human